The increase in costs of hospitalization for patients with drug-resistant infection may be associated with drug resistance itself or with the severity of the underlying illness that predisposes patients to acquire the drugresistant infection. To address this issue, risk factors and cost of hospitalization were compared for patients infected or colonized with vancomycin-susceptible Enterococcus faecium (VSEF) or vancomycin-resistant E. faecium (VREF) in a large tertiary-care hospital in New York City. From January 1995 through December 1996, 157 patients with VSEF and 262 patients with VREF were identified. CMI (case-mix index) was assigned to each patient as a measure of severity of illness, with a CMI of 1 considered to represent illness of average severity. For all patients who were assigned a CMI of !3, the cost per day of hospitalization for patients with VREF was significantly greater than that for patients with VSEF. However, for patients with a CMI of 13, there was no difference between cost of hospitalization for patients with VREF and that for patients with VSEF. These observations indicate that, although vancomycin resistance is associated with an increased cost of hospitalization for less severely ill patients with VREF, patients with severe underlying illness, regardless of vancomycin resistance, incur similar hospitalization costs.
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Enterococci are a leading cause of nosocomial infections in the United States. During 1989-1997, the National Nosocomial Infections Surveillance System reported that the percentage of vancomycin-resistant enterococci in nosocomial infections increased from 0.4% to 23.2% among patients in intensive care units and from 0.3% to 15.4% among patients in noncritical care units [1] . Since 1997, rates of vancomycin-resistant enterococci have continued to increase in both clinical settings [2] . Previous hospital-based studies have shown that infection or colonization with vancomycin-resistant Enterococcus faecium (VREF) is associated with prolonged hospitalization, patient transfer between floors, use of vancomycin and third-generation cephalosporins, and duration of vancomycin use [3] [4] [5] . Despite the institution of infection-control measures, including restriction of vancomycin use, VREF remains endemic in many hospitals, especially in large tertiarycare centers [2, 3] .
Bacterial infections caused by drug-resistant organisms have historically been associated with increased duration of hospitalization and higher mortality rates, compared with bacterial infections caused by drug-susceptible organisms, regardless of the pathogen [5, 6] .
However, few studies have focused on the magnitude of the contribution of resistant enterococci to hospital costs [7] [8] [9] . Prolonged hospitalization itself greatly increases hospital cost. It is not known, however, how much of the increased cost of hospitalization is associated with an organism that has acquired antimicrobial resistance. Differences in cost may be associated with factors other than drug resistance, such as differences in underlying medical conditions, which may predispose patients to develop drug-resistant infections.
We conducted a case-control study to examine this question by comparing risk factors and cost of hospitalization for patients who acquired VREF with those for patients who acquired vancomycin-susceptible E. faecium (VSEF) infection and colonization, by taking into consideration differences in the severity of the patients' underlying illness. The study was conducted in a tertiary-care hospital where patients with VREF infections were first identified in 1990 [10] and where a casecontrol analysis was previously performed to determine risk factors for VREF and VSEF infection and colonization that occurred from 1990 through 1992 [4] .
METHODS

Patients.
The study hospital was the New York Hospital, New York, a 988-bed tertiary-care hospital serving the New York metropolitan area. During 1995-1996, single patient isolates from patients who were infected or colonized with E. faecium were included in this case-control study. Patients were identified by a search of laboratory records from the clinical microbiology department. Only the first E. faecium isolate recovered from any patient was considered for analysis. Surveillance cultures of E. faecium were not included in this study. In our clinical microbiology laboratory, culture for E. faecium is not routinely performed on stool specimens submitted as clinical samples.
Clinical microbiology. All enterococcal isolates were identified using the automated Microscan Walkaway 96 (Dade Behring) with use of the freeze-dried Positive Breakpoint Combo 6 panel. By use of this method, Enterococcus casseliflavus and Enterococcus gallinarum are included in the identification of E. faecium. Therefore, all isolates identified as E. faecium were further tested by use of the stab motility test, in which cultures were incubated at 30ЊC for 24 h and were examined for both motility and production of a bright yellow pigment. During the study, the following single patient Enterococcus species (percentage prevalence) were identified: total number of inpatient and outpatient enterococcal isolates, 4181; Enterococcus faecalis, 3529 (84.4%); E. faecium, 575 (14.0%); Enterococcus avium, 28 (0.6%); Enterococcus durans, 26 (0.6%); E. gallinarum, 11 (0.2%); and E. casseliflavus, 6 (0.2%). Fifty-nine percent of the E. faecium isolates were resistant to vancomycin.
Definitions. A "case patient" was defined as a hospitalized person who had VREF isolated from any source from 1 January 1995 through 31 December 1996. A "control" was defined as a hospitalized person who had VSEF isolated from any source during the same period. Patients whose initial isolate was susceptible to vancomycin but who subsequently had VREF isolates recovered were included as case patients. Colonization by VREF or VSEF was defined according to the clinical and laboratory criteria previously reported by the Centers for Disease Control and Prevention, Atlanta [11] . Chart reviews. Demographic and clinical information was obtained from a review of patients' medical charts and the hospital's computerized information system (ADT System; Healthquest). The patient data that we collected are listed in table 1.
Cost data. Hospital cost data were obtained for each patient by the use of Decision Support System (Transitional Systems) computerized files. The cost data that were analyzed included the cost of each service to the hospital and not charges made to the patient or third-party payer. This cost-accounting system provided all quantitative routine and ancillary service costs. Routine service costs included those for room service, including utilities, administration, and nursing on the general floor and in intensive care units, step-down units, the operating room, and the recovery room. Ancillary service costs included those charged for such services and procedures as respiratory therapy, cardiac graphics, pulmonary function tests, clinical biochemistry assessments, determination of serum levels of vancomycin, blood bank laboratory tests, clinical hematologic tests, general radiologic examinations, nuclear medicine, ultrasound and CT, neuroradiologic examinations, physical therapy and rehabilitation, general microbiological tests, and general pharmacy, including all costs of antibiotics.
Case-mix index (CMI). The computerized DRG Resource Consumption Profile (Transitional Systems) was used to identify the following parameters for each patient: diagnosis-related group (DRG) number, DRG description, cost weight or CMI, duration of stay, principal diagnosis, principal procedure, and age. A cost weight was assigned to each DRG, and the proportion of the hospital's patients in each DRG was multiplied by this cost weight. The total of these cost weights provided the CMI [12] . An average CMI was provided by the hospital for the different study groups that we compared (patients with VREF and patients with VSEF). The average CMI for each study group is based on the sum of CMI values assigned to each patient in that group. CMI is based on the total number of hospital days during a patient's hospitalization. In this study, CMI was used as a surrogate measure of disease severity. On the basis of the national CMI average of 1, a CMI of р1 indicates average or below-average disease severity, whereas a CMI of 11 indicates above-average disease severity.
Statistical analysis. . Multivariate analysis was done with the use of logistic regression; significant variables were selected by use of a backward stepwise procedure. All P values reported in this study are 2-sided.
RESULTS
From 1 January 1995 through 31 December 1996, 419 inpatients were identified and included in the study. Of these 419 inpatients, 157 (37%) had VSEF isolates recovered (controls), and 262 (63%) had VREF isolates recovered (case patients).
Risk factors for VREF infection. The comparative demographic and clinical features for both case patients and controls are listed in table 1. There was a significant difference in the age distribution of case patients and controls; the mean age of the case patients was 60 years, and that of the controls was 51 years ( ). Individuals aged !10 years were less likely to P ! .001 have VREF isolates recovered (OR, 0.25; 95% CI, 0.12-0.51), whereas individuals aged 150 years had a greater risk for VREF infection or colonization (OR, 1.66; 95% CI, 1.08-2.56).
Case patients were hospitalized for a longer period than were controls: case patients were hospitalized for a mean duration of 49 days, and controls were hospitalized for a mean duration of 34 days (
). In addition, case patients were more P p .004 likely to be hospitalized for 17 or 114 days than were controls. The interval from admission to the hospital until a positive culture result was obtained was longer for case patients than for control patients (26 days vs. 15 days, respectively; P p ). .0002
Other risk factors for VREF infection included the following: location on the medical service; location in an intensive care unit; intrahospital transfer to 11 floor; isolation of E. faecium from a source other than a urine or blood sample or a wound; and hemodialysis. In addition, both use of third-generation cephalosporins, gentamicin, ciprofloxacin, or vancomycin, and use of у2 of these antibiotics plus ampicillin were also associated with VREF infection or colonization. The ORs (95% CIs) associated with the use of antibiotics were as follows: for third-generation cephalosporins, 2.97 (1.92-4.60); for vancomycin, 2.11 (1.37-3.25); and for use of multiple antibiotics, 2.40 (1.50-3.84). As shown in table 2, the only risk factors that were significant in predicting VREF infection or colonization by multivariate analysis were hemodialysis (OR, 2.9; 95% CI, 1.4-5.8) and intrahospital transfer to 11 floor (OR, 1.8; 95% CI, 1.2-2.9). On the other hand, the following variables were associated with protection from VREF infection in the multivariate analysis: location on the obstetric, gynecologic, or neonatal service (OR, 0.14; 95% CI, 0.3-0.6); previous gastrointestinal surgery (OR, 0.36; 95% CI, 0.2-0.6); and age !10 years (OR, 0.45; 95% CI, 0.2-0.9).
Mortality. During 12,775 person-days of hospitalization for patients with VREF, 107 patients died; during 5373 persondays of hospitalization for patients with VSEF, 32 patients died. Therefore, the mortality rate per 100 person-days of hospitalization was 0.84 for patients with VREF and 0.6 for patients with VSEF ( ). Mortality rates for which CMI was con-P 1 .05 trolled were also compared. For patients with a CMI of р4, the mortality rate per 100 person-days of hospitalization was 1.4 for patients with VREF, compared with 1.0 for patients with VSEF (
). For patients with a CMI of 14, the mortality P 1 .05 rate was 0.6 for patients with VREF, compared with 0.4 for patients with VSEF ( ). P 1 .05 Duration of hospitalization. There was no difference in the number of days that case patients and controls were hospitalized after a culture that was positive for E. faecium was obtained (mean, 24 days vs. 19 days, respectively). In addition, there was no difference in the duration of hospitalization of patients with E. faecium (VREF or VSEF) bacteremia versus patients with E. faecium that was isolated from a source other than blood. For all patients with VREF infection or colonization, there was no difference in the duration of hospitalization of patients with bacteremia versus patients with VREF isolated from a source other than blood. Patients with VSEF bacteremia were hospitalized for a mean of 56 days, and patients with VSEF isolated from a source other than blood were hospitalized for a mean of 30 days ( ). P ! .01 CMI and cost of hospitalization analysis. The CMI ranking was known for 388 patients (93%) in the study population. There was no difference in the percentage of case patients (91%) and controls (96%) who had an assigned CMI. The mean CMI of the study population was 6.14, and the median CMI was 3.47 (range, 0.58-25.97). The mean CMI (‫ע‬SD) for case patients ( ) was 6.63 ‫ע‬ 6.62, and the mean CMI for n p 238 controls ( ) was 5.37 ‫ע‬ 6.20 ( ). n p 150 P p .06 For all patients with a CMI of 11, the odds of being a case patient were 2.75 (95% CI, 1.28-5.94) times greater than the odds of being a control. For patients with a CMI of 12, the odds of being a case patient were 1.78 (95% CI, 1.09-2.91) times greater than the odds of being a control. There was no significant difference in the odds of being a case patient or a control when the CMI was 13 ( ).
The total observed cost of hospitalization was $27,541,955 for the 262 patients with VREF and $10,130,607 for the 157 patients with VSEF. The cost per day of hospitalization was $2156 for patients with VREF and $1855 for patients with VSEF, Variables that were found to be significantly more costly for patients with VREF infection or colonization included female sex, age 150 years, hospitalization on the surgical service, presence of an underlying benign gastrointestinal disorder, and previous surgical or gastrointestinal surgical procedure.
The difference in hospital costs for patients with VREF versus patients with VSEF was also examined on the basis of severity of illness. The total cost per person-day of hospitalization was not significantly greater ($278 more;
) for all patients P 1 .05 with VREF or VSEF who had a CMI of 11, compared with all patients with VREF or VSEF who had a CMI of р1. However, among patients with a CMI of р1, the total cost per personday of hospitalization for patients with VREF was significantly greater ($543 more) than that for patients with VSEF (P ! ); for patients with a CMI of 11, the difference between .01 patients with VREF and patients with VSEF was $244 (P 1 ). The difference in average cost per person-day for case .05 patients and controls who were stratified according to CMI is shown in table 4. For case patients and controls with a CMI of 13, there was no difference in the mean cost per personday of hospitalization (for case patients, $2477; for controls, $2429; mean difference, $47;
). However, among case P 1 .05 patients and controls who had a CMI of р3, a significant difference in the mean cost per person-day was observed (for case patients, $2269; for controls, $2016; mean difference, $252;
).
By multivariate analysis, no cost component was found to be significantly greater for case patients than for controls (data not shown). Among patients who were hospitalized for longer than the mean duration of hospitalization (143 days), patients with VREF had a significantly greater total cost per day of hospitalization than did patients with VSEF ($436 more; P ! ). The cost of hospitalization was $471 more per day for .05 patients with VREF or VSEF who had bacteremia than it was for patients who had E. faecium isolated from another source ( ). Among 57 patients with VREF and 24 patients with P ! .002 VSEF who had bacteremia, the cost of hospitalization was not significantly affected by the vancomycin-resistance status of the E. faecium isolate ( ). P ! .34
DISCUSSION
The objective of this study was to determine the risk factors for VREF infection or colonization among inpatients at a tertiary-care hospital in which VREF had been endemic since 1992; we also wanted to assess whether and how VREF is associated with increased costs of hospitalization, prolonged hospitalization, and mortality rates. One question we wished to address was whether glycopeptide resistance of E. faecium per se is associated with an increased cost of hospitalization. The large number of both groups of patients in the study hospital provided an opportunity to control for the severity of underlying illness among patients with VREF and patients with VSEF, thereby allowing us to examine this question in depth.
By multivariate analysis, we found that intrahospital transfer (OR, 1.8) and hemodialysis (OR, 2.9) were associated with VREF infection or colonization. To our knowledge, this is the first documentation that dialysis is an independent variable for the acquisition of VREF [4, 14, 15] . A previous study with a comparable sample size, performed at our hospital in 1990-1992, identified hospitalization of у7 days' duration, intrahospital transfer, and use of vancomycin and third-generation cephalosporins as being independently associated with VREF infection or colonization [4] . Of interest, in the study reported here, which was performed during 1995-1996, vancomycin use was not found to be a risk factor for VREF by multivariate analysis. In a medical setting in which VREF has become endemic, the association with vancomycin use may become obscured because a large number of patients with VREF colonization may serve as a source for already-resistant strains of E. faecium in patients who have not necessarily received glycopeptide antibiotics [2, 3] . In this study, we used CMI as a surrogate measure for disease severity. The national average CMI is 1, and the average CMI in our tertiary-care hospital during the study period was 1.6. However, the average CMI in our study population was 6.14, reflecting in part the severity of underlying illnesses in patients with E. faecium infection or colonization. We found that the total cost of hospitalization in our study depended both on the patient's severity of illness and on the resistance status of the E. faecium isolate. VREF significantly increased the total cost per person-day of hospitalization for patients with a CMI of р1 ($543) or a CMI of р3 ($252), but not for those with a CMI of 13. Therefore, the acquisition of vancomycin resistance by E. faecium appears to be associated with an increase in the cost of hospitalization for less severely ill patients who are infected or colonized with E. faecium, regardless of the underlying nature of the illness. However, for patients with severe illness (CMI, 13) , the cost of hospitalization for the underlying illness appears to obscure the effect of the increased cost of hospitalization associated with vancomycin resistance.
It should be noted that the calculation of CMI is based both on the type of illness and the cost of treatment for that illness. The CMI coding system may misclassify CMI by not indicating all cofactors and degrees of illness [12] . If the CMI used in this study misclassified the severity of illness, then the difference in costs for patients with VREF and patients with VSEF would more likely be biased toward the null, or there would be no apparent trend in the difference between costs of hospitalization for patients with VREF versus patients with VSEF, with regard to assignment of a low or high CMI. In this study, CMI determinations did show an increased cost of hospitalization for patients with VREF only at the lower level of CMI, which suggests that the coding system was valid as used in this study.
Overall, patients with VREF were more likely to have a severe illness than were patients with VSEF, as measured by CMI. However, there was no significant difference in the proportions of patients with VREF or VSEF who had a CMI of 13. Previous studies have shown that severity of illness, as measured by the Acute Physiology and Chronic Health Evaluation II score, is a significant risk factor for VREF bacteremia in multivariate analysis [16] . Our results are consistent with these findings. However, the prevalence of VREF infections in a hospital may depend more on the type of underlying illness itself than on the severity of an illness. The highest OR (2.9), identified by multivariate analysis, among risk factors for VREF isolation in this study was for hemodialysis. Patients who require hemodialysis often have complicating illnesses and may receive multiple courses of antibiotics, including vancomycin, which places them at greater risk for VREF infection or colonization. Frequent hospitalizations and cross-transmission can also contribute to VREF infection or colonization in patients undergoing hemodialysis [17, 18] .
From 1990 through 1992, at our institution, patients with VREF had a longer duration of hospitalization (mean, 64.5 days) than did patients with VSEF (mean, 40.8 days) [4] . In the present study, patients with VREF also had a longer duration of hospitalization (mean person-days, 48.8) than did patients with VSEF (mean person-days, 34.2;
). However, this P ! .05 longer duration of hospitalization did not fully explain the difference in the cost of hospitalization. Among all patients who were hospitalized for longer than the mean duration of hospitalization (143 days), patients with VREF had a significantly greater total cost per day of hospitalization ($436; P ! ) than did patients with VSEF. Therefore, the difference in .05 duration of hospitalization for patients with VREF versus patients with VSEF is not the only factor that contributes to increased costs of hospitalization for patients with VREF.
Among patients who had bacteremia, VREF infection was not associated with increased cost of hospitalization, compared with presence of VSEF bacteremia. VSEF bacteremia (but not VREF bacteremia) increased the duration of hospitalization, compared with nonbacteremic infections, suggesting that patients with VSEF bacteremia had more severe underlying illness than did patients with VSEF who did not have bacteremia. Although earlier studies suggested an increased mortality rate among patients with VREF bacteremia [19, 20] , other studies, including the present report, have shown no difference between patients with VREF bacteremia and those with VSEF bacteremia after controlling for severity of illness [16, 21, 22] .
The observations made in this study support the notion that vancomycin-resistant E. faecium is associated with increased hospitalization costs in a subset of VREF-infected or -colonized patients. Controlling for severity of illness, we found that patients with a CMI of р3 had a greater mean cost per personday of hospitalization than did patients with VSEF infection or colonization. Among all patients who were hospitalized for longer than the mean duration of hospitalization (43 days), patients with VREF had a greater mean cost of hospitalization. However, for patients with severe underlying illness (suggested by a CMI of 13 or the presence of bacteremia), the influence of the illness itself contributed to increased cost of hospitalization, obscuring the association with drug resistance. Because all patients colonized with VSEF serve as a reservoir and potential source for VREF, our data indicate that prevention of the emergence of VREF should contribute substantially to savings in hospital costs.
